Additionally, the FDA’s Division of Neurology I granted its request for a pre-IND meeting for discussing a development path for elamipretide along with products within the approved exon-skipping
The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with
The financing round saw participation from other new investors Pavilion Capital, Section 32, Invus and LifeSci Venture Partners. All of the Series A investors of Moma including Third
Under the agreement terms, Arvinas will leverage the Gemini Virtual Patient models of GNS to gain better understanding of the biology of the underlying disease. Arvinas will understand
The company will use these funds to expedite IN10018’s clinical trials that are currently underway for several types of cancer in the US as well as China, including
These patients have inadequate response to corticosteroids or other systemic therapies. Jakavi, an oral JAK 1 and JAK 2 tyrosine kinases inhibitor, was licensed by Novartis from Incyte
Other new investors Alpha Wave Ventures, NexPoint also participated in the round along with existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners. Apnimed will use the
This is the third orphan drug designation received by Sapience for ST101, a first-in-class peptide antagonist of C/EBPβ. The FDA granted orphan designations to ST101 for AML treatment
With over a hundred years of experience, Intravacc is a contract development and manufacturing organization (CDMO) of vaccines against infectious diseases. A vaccine company in China, Zhifei Lvzhu
Qelbree now received approval for ADHD treatment in children starting at the age of six, adolescents as well as adults. Supernus Pharmaceuticals president and CEO Jack Khattar said:
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.